Gritstone Unveils "Off-The-Shelf" Neoantigen Immunotherapy Data In Lung Cancer

  • Gritstone bio Inc GRTS has announced results with its SLATE v1 product ("off-the-shelf" shared neoantigen immunotherapy).
  • The therapy is in combination with Bristol-Myers Squibb Co's BMY intravenous Opdivo (nivolumab) and subcutaneous Yervoy (ipilimumab). The Company has also dosed the first patient in Phase 2 trial of the optimized SLATE v2 product. 
  • SLATE v2 has been engineered to drive a more potent immune response to mutant KRAS neoantigens than were observed with SLATE v1.
  • SLATE v1 exhibited efficacy in patients with NSCLC who had all progressed on prior anti-PD-(L)1 therapy with molecular responses observed in 3/5 NSCLC patients who were eligible for analysis.
  • Among 6 NSCLC patients, ctDNA responses were observed in 66% of these patients (2/3 eligible for analysis). An unconfirmed radiologic response was observed in one 2nd line patient who had progressed after three months of 1st line chemo-immunotherapy. 
  • One patient who had progressed on prior chemo-immunotherapy after eight months of treatment is nearing completion of 2 years of therapy with persistent ~20% tumor lesion shrinkage. The patient's ctDNA was undetectable throughout the study.
  • The SLATE v2 Phase 2 portion of the study will enroll up to 60 patients with KRAS mutant-driven tumors in total across three cohorts.
  • Price Action: GRTS shares are up 3.69% at $14.04 during the premarket session on the last check Friday.
Loading...
Loading...
BMY Logo
BMYBristol-Myers Squibb Co
$48.290.92%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
47.29
Growth
70.56
Quality
Not Available
Value
29.72
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...